Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2026 11:18 ET | Source: Research and Markets

Vitiligo Treatment Market Report 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast to 2031

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's...
January 21, 2026 09:00 ET | Source: Human Continuum Inc.

Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products

New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced...
January 16, 2026 04:56 ET | Source: Research and Markets

Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends

Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The "Dermatology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The dermatology market is undergoing a...
January 10, 2026 17:24 ET | Source: Natura Pro Skin Tag Remover

Best Natural Skin Tag Remover 2026: Natura Pro Skin Tag Remover Ingredient Analysis, Safety Facts, and Consumer Guidance

Best natural skin tag remover? Natura Pro Skin Tag Remover bloodroot botanical formula and at-home removal options examined for consumers in 2026
January 07, 2026 16:05 ET | Source: Turn Therapeutics

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for...
January 07, 2026 11:40 ET | Source: Research and Markets

Glabellar Frown Lines Market Analysis and Demand Forecast, 2025-2035, with Regional Insights

Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The "Glabellar Frown Lines Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ...
January 06, 2026 07:00 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 05, 2026 17:00 ET | Source: Alumis Inc.

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
December 29, 2025 09:00 ET | Source: American Society for Dermatologic Surgery

Dermatologic Surgery Journal Releases Special Issue on Facial Assessment in a Diverse World

Schaumburg, IL, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Dermatologic Surgery, the official scientific journal of the American Society for Dermatologic Surgery (ASDS), has published a special issue on...
December 23, 2025 05:00 ET | Source: InnoCare Pharma

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.